29 results on '"Stern, J.O."'
Search Results
2. P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVR
3. P1226 NS3 Q80K DID NOT IMPACT EFFICACY OR TREATMENT-EMERGENT RESISTANCE PATTERNS IN HCV GENOTYPE 1-INFECTED PATIENTS RECEIVING FALDAPREVIR + PEGINTERFERON/RIBAVIRIN IN THREE PHASE III TRIALS
4. P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS
5. P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL
6. P1125 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF TWO PHASE III TRIALS
7. P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES
8. P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS
9. P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS
10. P1227 FALDAPREVIR EFFICACY IN HCV GENOTYPE-1-INFECTED PATIENTS IN FOUR PHASE 3 TRIALS: ANALYSIS BY NS3 BASELINE POLYMORPHISMS, GENOTYPE-1 SUBTYPE AND GENOTYPE-1A CLADES
11. P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS
12. O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN
13. P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE
14. P721 INTERFERON-STIMULATED GENE EXPRESSION IS ASSOCIATED WITH TREATMENT RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION
15. P1133 COMPARISON OF 24 AND 48 WEEKS OF TREATMENT WITH FALDAPREVIR AND PEGYLATED INTERFERON/RIBAVIRIN IN PATIENTS WITH DETECTABLE BUT NOT QUANTIFIABLE HCV RNA AT WEEK 4
16. 1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL
17. 1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2
18. 1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY
19. 1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS
20. 101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2
21. 1209 IMPACT OF EARLY RESPONSE DEFINITIONS ON DURATION AND OUTCOME OF TREATMENT WITH BI201335 PLUS PR
22. 66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R
23. 60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
24. 1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV
25. 1249 BI201335 PHARMACOKINETICS AND EARLY EFFECT ON VIRAL LOAD IN HCV GENOTYPE-1 PATIENTS
26. 954 BI 201335, A POTENT HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE AND -EXPERIENCED CHRONIC HCV GENOTYPE-1 INFECTION: GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE NS3 PROTEASE DOMAIN
27. A model compound for nitrosyl cytochrome P-450; further evidence for mercaptide sulfur ligation to heme
28. A Model Compound Study of the CO-Adduct of Cytochrome P-450
29. A low-temperature EPR study of partially purified, soluble ferric cytochromes P-450 and P-448 from rat liver microsomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.